Search clinical trials for: ATM001 Placebo

Total 54059 results

Baliopharm Pty Ltd

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

Healthy Volunteers

Australia
AmDerma

Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Skin Diseases | Skin Diseases, Papulosquamous | Plaque Psoriasis

United States
Massachusetts General Hospital

Terminated

AT1001 for the Treatment of COVID-19 Related MIS-C

Covid19 | Multisystem Inflammatory Syndrome in Children

United States
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Acute Ischemic Stroke

China
AriBio Co., Ltd.

Recruiting

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Alzheimer Disease

Korea, Republic of, United States, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Germany, Poland, United Kingdom, Netherlands, Argentina
AJNA Australia Pty Ltd

Active, not recruiting

A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects

Healthy Volunteers

Australia
Avotres Inc.

Active, not recruiting

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
AriBio Co., Ltd.

Completed

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Mild to Moderate Alzheimer's Disease

United States
Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
Frontier Biotechnologies Inc.

Completed

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

Chronic Low Back Pain

United States
9 Meters Biopharma, Inc.

Completed

Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

Celiac Disease

Canada, United States
Basilea Pharmaceutica

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
UNION therapeutics

Completed

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Irritation Potential of Topic Agent

United States
Zhuhai Trinomab Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Respiratory Syncytial Virus Infections

China
Trinomab Biotech Co., Ltd.

Recruiting

A Study of TNM001 in Chinese Healthy Preterm and Term Infants

Respiratory Syncytial Virus Infections

China
Massachusetts General Hospital

Recruiting

AT1001 for the Treatment of Long COVID

Post Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19

United States
AmDerma
International Dermatology Research, Inc.

Completed

Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis

Plaque Psoriasis

Dominican Republic
Lumosa Therapeutics Co., Ltd.

Unknown

A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS

Acute Ischemic Stroke

Taiwan, United States
Achilles Therapeutics UK Limited

Terminated

Long-Term Follow-Up Study of Patients Receiving ATL001

Melanoma | Advanced Non Small Cell Lung Cancer

United Kingdom
Lumosa Therapeutics Co., Ltd.

Unknown

Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients

Uremic Pruritus

Taiwan
Enterprise Therapeutics Ltd

Completed

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Cystic Fibrosis

United Kingdom
Allakos Inc.

Completed

Study to Evaluate Multiple Doses in Patients With Nasal Polyposis

Nasal Polyposis

Belgium, United States, Germany, Netherlands, Spain, United Kingdom
Shenzhen Turier Biotech Co., Ltd

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 in Healthy Subjects

Healthy

China
Basilea Pharmaceutica

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Adrian Hernandez
Massachusetts General Hospital; Mayo Clinic; National Heart, Lung, and Blood... and other collaborators

Completed

Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF)

Heart Failure

United States
Lumosa Therapeutics Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects (BRIGHT)

Acute Ischemic Stroke
Lumosa Therapeutics Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

Acute Ischemic Stroke
AmDerma

Completed

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

Actinic Keratosis

United States
Shanghai JunTop Biosciences Co., LTD
Sponsor GmbH

Terminated

JT001 (VV116) for the Early Treatment of COVID-19

Mild to Moderate COVID-19

China, Hong Kong
Amicus Therapeutics

Completed

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Fabry Disease

United States, Italy, Spain, Turkey, Brazil, Canada, United Kingdom, France, Poland, Australia, Egypt, Argentina, Denmark
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

JT001 (VV116) for the Treatment of COVID-19

Mild to Moderate COVID-19

China
Alector Inc.

Terminated

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Amyotrophic Lateral Sclerosis

United States
Amicus Therapeutics

Approved for marketing

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Fabry Disease

United States, Australia
Jetema USA Inc.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Glabellar Lines
AlgoTherapeutix

Recruiting

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) (ACT)

Chemotherapy-induced Peripheral Neuropathy

United States, Spain, Belgium, France, Czechia, Poland, Italy
AiViva BioPharma, Inc.

Completed

A Safety and Efficacy Study to Evaluate Wound Healing

Wound Heal

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Terminated

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Moderate to Severe COVID-19

China, Uzbekistan
Amicus Therapeutics

Completed

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

Fabry Disease

United Kingdom, United States
Strekin AG

Completed

Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL

Acute Hearing Loss

Switzerland, Czechia, Germany
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
Amicus Therapeutics

Active, not recruiting

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

Fabry Disease

United States, United Kingdom
Amicus Therapeutics

Completed

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

Fabry Disease

United States
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (IMAGO)

Alagille Syndrome

United Kingdom
UNION therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis

Canada
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) (ICONIC)

Alagille Syndrome

France, Belgium, Poland, Australia, Spain, United Kingdom
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
Amicus Therapeutics

Completed

A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)

Fabry Disease
Amicus Therapeutics

Completed

A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

Fabry Disease

Australia

3

Subscribe